---
title: "Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298782816.md"
description: "Tyra Bioscience director Verjee Rehan purchased 971 shares worth $19,973 on Sept 11, 2026, signaling confidence. This move follows a sharp stock drop due to weaker-than-expected Phase 2 SURF302 efficacy data for dabogratinib in NMIBC, prompting analysts to cut price targets. Despite the downturn, the long-term thesis remains intact. TipRanks AI rates TYRA as Neutral, citing weak financials and technical downtrends offset by a low-debt balance sheet."
datetime: "2026-09-12T02:06:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298782816.md)
  - [en](https://longbridge.com/en/news/298782816.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298782816.md)
generator: "portal-rs"
---

# Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead

New insider activity at Tyra Bioscience ( (TYRA) ) has taken place on September 11, 2026.

Director Verjee Rehan recently increased his stake in Tyra Bioscience by purchasing 971 shares of the company’s stock in a transaction valued at $19,973, signaling a fresh vote of confidence from inside the firm’s leadership.

Tyra Biosciences shares fell sharply in the last 24 hours after initial Phase 2 SURF302 efficacy data in FGFR3‑altered intermediate‑risk NMIBC were viewed as weaker than previously hoped, despite favorable safety and proof of concept for oral dabogratinib. Analysts cut price targets mainly because the “lukewarm” efficacy versus expectations reduces perceived upside and lengthens the path to peak adoption, even though the long‑term thesis for a convenient oral adjuvant therapy in a large, undertreated market and expansion into other FGFR3‑driven indications remains intact.

**Spark’s Take on TYRA Stock**

According to Spark, TipRanks’ AI Analyst, TYRA is a Neutral.

The score is held down primarily by weak financial performance consistent with a pre-revenue biotech (widening losses and substantial, worsening cash burn). Technicals also detract due to a clear downtrend (price below key moving averages and negative MACD). Offsetting these risks are a low-debt balance sheet that reduces solvency pressure and a meaningful positive corporate event with promising Phase 2 data that may improve the company’s clinical and commercial outlook.

To see Spark’s full report on TYRA stock,  
 click here. 

**More about Tyra Bioscience**

**YTD Price Performance:** -10.46%

**Average Trading Volume:** 845,343

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $1.31B

### Related Stocks

- [TYRA.US](https://longbridge.com/en/quote/TYRA.US.md)

## Related News & Research

- [TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY | TYRA Stock News](https://longbridge.com/en/news/287215316.md)
- [INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA](https://longbridge.com/en/news/298654242.md)
- [Faraday Future shifts to robotaxi sharing network, AI VisiCabin operator model](https://longbridge.com/en/news/301835634.md)
- [SK Hynix Stocks Fall 1.7% Although January Deadline Advances Its AI Flash Roadmap](https://longbridge.com/en/news/301879674.md)
- [TSMC Q3 Earnings Preview: Can Profit Hit a Record High for a Sixth Straight Quarter? Wall Street's Highest Target Price Is $665](https://longbridge.com/en/news/301683133.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**